FDA accelerated approval benefits glioblastoma.
Timothy
T
Cloughesy
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017277:Drug Approval; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D000077204:Temozolomide; D014481:United States; D014486:United States Food and Drug Administration
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide